LONDON (Alliance News) - Midatech Pharma PLC said Thursday that it is "not aware of any reason" behind the sharp drop in its share price.
Midatech shares were down 22% at 35.80 pence each Thursday midday.
The oncology-focused pharmaceutical company noted its previously announced financial results for the year ended 2017 where it outlined a range of non-dilutive financing options that, if successful, would allow the company to deliver its "key value-driving programmes" without requiring equity finance in the short-term.
Midatech said it remains on track to deliver all research & development programmes.
